Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.
- DOI
- 10.1038/s41409-025-02557-7
- Published
- 2025 Jun
- Container
- Bone marrow transplantation
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41409-025-02557-7,
title = {Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.},
author = {Sureda A and Pavlovsky A and Haidar D and Kristo F and Stache V and Zomas A},
year = {2025},
journal = {Bone marrow transplantation},
doi = {10.1038/s41409-025-02557-7},
url = {https://doi.org/10.1038/s41409-025-02557-7}
}RIS
TY - JOUR TI - Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis. AU - Sureda A AU - Pavlovsky A AU - Haidar D AU - Kristo F AU - Stache V AU - Zomas A PY - 2025 JO - Bone marrow transplantation DO - 10.1038/s41409-025-02557-7 UR - https://doi.org/10.1038/s41409-025-02557-7 ER -
APA
A, S., A, P., D, H., F, K., V, S., & A, Z. (2025). Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis.. Bone marrow transplantation. https://doi.org/10.1038/s41409-025-02557-7
Source records
- pubmed · retrieved 2026-09-27T00:37:22.355Z
- europe-pmc · retrieved 2026-09-27T00:37:22.359Z